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Abstract
Purpose—Recent studies demonstrate that whole-genome sequencing (WGS) enables detection 
of cryptic rearrangements in apparently balanced chromosomal rearrangements (also known as 
balanced chromosomal abnormalities, BCAs) previously identified by conventional cytogenetic 
methods. We aimed to assess our analytical tool for detecting BCAs in The 1000 Genomes Project 
without knowing affected bands.
Methods—The 1000 Genomes Project provides an unprecedented integrated map of structural 
variants in phenotypically normal subjects, but there is no information on potential inclusion of 
subjects with apparently BCAs akin to those traditionally detected in diagnostic cytogenetics 
laboratories. We applied our analytical tool to 1,166 genomes from the 1000 Genomes Project 
with sufficient physical coverage (8.25-fold).
Results—Our approach detected four reciprocal balanced translocations and four inversions 
ranging in size from 57.9 kb to 13.3 Mb, all of which were confirmed by cytogenetic methods and 
PCR studies. One of DNAs has a subtle translocation that is not readily identified by chromosome 
analysis due to similar banding patterns and size of exchanged segments, and another results in 
disruption of all transcripts of an OMIM gene.
Conclusions—Our study demonstrates the extension of utilizing low-coverage WGS for 
unbiased detection of BCAs including translocations and inversions previously unknown in the 
1000 Genomes Project.
Keywords
balanced chromosomal rearrangement; the 1000 Genomes Project; G-banded chromosome 
analysis; low-pass whole-genome sequencing
Introduction
A balanced chromosomal rearrangement (or abnormality, BCA) is a type of chromosomal 
structural variant (SV) involving chromosomal rearrangements (e.g., translocations, 
inversions and insertions) without cytogenetically apparent gain or loss of chromatin. The 
incidence of balanced translocations has been estimated to range from 1/500 to 1/625 in the 
general population1–3 and the prevalence is well known to be increased in individuals with 
clinical anomalies4–7. Based on the association of increased prevalence with abnormal 
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clinical phenotypes, studies of BCA such as in the Developmental Genome Anatomy Project 
(DGAP)5,6,8,9 among others7,10 have a high yield in identification of genetic disease due to 
gene disruption or dysregulation.
Current high-resolution methods (i.e., chromosomal microarray analysis and whole exome 
sequencing) are generally insensitive to BCA that are unaccompanied by sizable genomic 
imbalances. Thus, detection of BCA relies on conventional cytogenetic methods (i.e., G-
banded karyotyping), which are limited to microscopic resolution (~3–10 Mb). More 
recently, whole-genome sequencing (WGS) using paired-end analysis has enabled molecular 
delineation of the breakpoints of BCA at base-pair resolution but has been tested and 
validated only in DNA samples harboring previously recognized BCAs.
By utilizing WGS (mean 7.4-fold base-coverage) and orthogonal techniques (i.e., long-read 
single-molecule sequencing), the 1000 Genomes Project establishes the most detailed 
catalogue of human genetic variation, which in turn can be used for association studies 
relating genetic variation to disease. It provides an unprecedented integrated map of SVs 
from 2,054 individuals, including copy-number variants, inversions (< 50 kb) and 
insertions11,12, and serves as an indispensable reference for geographic and functional 
studies of human genetic variation. However, no information was available on the frequency 
of balanced translocations or inversions (> 50 kb in size) in this resource of participants who 
were healthy at the time of enrollment. Our previous pilot study has shown the feasibility of 
detecting BCA with low-pass (or low-coverage) paired-end WGS in a blinded fashion13. In 
the present study, we apply our analytical tool to WGS data released by the 1000 Genomes 
Project11.
Materials and Methods
WGS data from the 1000 Genomes Project
Alignment files from 2,504 presumably healthy individuals were downloaded from the 1000 
Genomes Project. Assessment of data quality and further analysis was processed for each 
individual independently.
Minimum physical coverage requirement used in this study
As shown in our previous study13, the minimum read-pair count was used to avoid false 
negative detection of BCA. This minimum number of read-pairs in a small-insert library 
(400 to 600 bp) was estimated as 120 million (50 bp), which is equivalent to 4-fold base 
coverage from whole-genome sequencing. However, read length (35 to 100 bp) and insert 
size (200 to 600 bp, Figure 1A) were varied among samples from the 1000 Genomes 
Project11. Therefore, physical coverage14 was used as the required selection criteria instead 
of the number of read-pairs (Figure 1B).
We defined a chimeric read-pair if two ends aligned to different chromosomes 
(interchromosomal) or to the same chromosome (intrachromosomal) with an aligned 
distance larger than 10 kb13,15. Physical coverage was estimated by counting the aligned 
distances from the non-chimeric and uniquely mapped read-pairs13. In the present study, the 
minimum physical coverage of 8.25-fold, estimated based on 90 million read-pairs (data 
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from our previous pilot study)13, was set to maximize inclusion of 1,166 out of 2,504 
samples (Supplementary Table 1). This was based on: (1) only 616 out of 2,504 samples 
available for this study with 11-fold physical coverage (estimated based on 120 million read-
pairs), and (2) an increase in the false negative detection rate in our previous study from 
11.1% (1/9) with 90 million read-pairs to 33.3% (3/9) with only 60 million read-pairs13.
Data quality control and BCA detection
We filtered out low-quality reads (≥ 4% of mismatch rates) and extracted uniquely aligned 
reads in both ends for further analysis. Detection of chromosomal rearrangement is based on 
a four-step procedure described in our previous study13: briefly, (1) Event clustering: 
chimeric read-pairs were clustered by sorting the aligned coordinates (GRCh37/hg19) and 
any two read-pairs were considered to represent two distinct events if they were separated by 
a distance of >10 kb; (2) Systematic error filtering: Each event was filtered against a control 
dataset, which was built up by using the events from all the 2,504 samples, and a false 
positive was filtered out if it was identified in more >5% subjects; (3) Random error 
filtering: Event was filtered with a cluster property matrix (i.e., supporting read-pair amount 
and the average number of mismatches) with the reported parameters; and (4) Aligned 
orientations: each event was filtered based on q/p arm genetic exchange (joining type). As 
some of the samples were with short read lengths (i.e., 35 bp), we further used Sanger 
sequencing results to fine map the ligated sequences ate the breakpoints.
Chromosome analysis and FISH validation
Epstein-Barr virus (EBV)-transformed B lymphoblastoid (EBV-B) cell lines were obtained 
from the Coriell Institute (Camden, NJ) for validation. G-banded chromosome analysis was 
performed using standard protocols for more than 100 cells in each EBV-B cell line16. 
Fluorescence in situ hybridization (FISH) was performed for NA18612 using standard 
procedures with BAC clones labeled by nick translation with SpectrumOrange or 
SpectrumRed, SpectrumGreen dUTP (Abbott Molecular, Des Plaines, IL)16,17. BAC clones 
were selected from the UCSC Genome Browser.
Molecular validation of balanced rearrangements
For samples with translocations and available EBV-B cell lines, genomic DNA was extracted 
using a commercial DNA extraction kit (Puregene; Qiagen, Hilden, Germany). For samples 
identified with submicroscopic inversions, DNAs were obtained from the Coriell Institute 
(Camden). Each DNA was quantified subsequently with the Qubit dsDNA HS Assay Kit 
(Invitrogen, Life Technologies, Waltham, MA) for DNA quality measurement.
Genomic reference sequences (GRCh37/hg19) at a 1 kb distance from each putative 
breakpoint region (both upstream and downstream) were used for primer design with 
Primer3 Web and NCBI Primer-Blast (Supplementary Table 2). PCR amplification was 
performed simultaneously in cases and control (DNA from YH, a well-characterized normal 
EBV-B cell line18). PCR products were sequenced by Sanger sequencing on an ABI 3730 
machine (Applied Biosystems, Thermo Fisher Scientific Inc, Wilmington, DE)8,13,19 and 
sequencing results were aligned with BLAT for further confirmation of the balanced 
rearrangement and for mapping breakpoints at single nucleotide level.
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RNA preparation, library construction and sequencing
Total RNA was extracted from each EBV-B cell line with a balanced translocation using 
TRIzol Reagent (Invitrogen) according to the manufacturer’s instructions, and subsequently 
treated with DNase I (Invitrogen)20. For each RNA sample, purity was evaluated with a 
Nano-Photometer spectrophotometer (Implen, Westlake Village, CA), concentration 
measured in a Qubit 2.0 Fluorometer (Life Technologies), and RNA integrity verified using 
an Agilent 2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA).
For library construction, mRNA enrichment was performed with Oligo(dT)25 Dynabeads 
(Thermo Fisher Scientific) twice and purification was carried out with the Dynabeads® 
mRNA Purification Kit (Invitrogen, No. 61006). The eluted mRNA was fragmented with 
Fragmentation Buffer Mix at 94℃ for 10 min. Reverse transcription (RT) was performed 
with RT Buffer Mix and RT Enzyme Mix followed by double strand cDNA (dscDNA) 
synthesis with Second Strand Buffer Mix and Second Strand Enzyme Mix. End repair, 
adaptor (with barcode) ligation and PCR amplification were performed after dscDNA 
purification. Then, the purified double stranded PCR products were heat denatured to single 
strand and circularized with Splint Oligo Mix and Ligation Enzyme. The single strand circle 
DNA (ssCirc DNA) library was rolling circle amplified for constructing the DNA nanoball 
(DNB), which was substantially loaded into a patterned nanoarray. Paired-end sequencing 
with 50 bp in each end (PE50) was carried out in a BGISeq-500 platform (BGI, Wuhan, 
China)21.
RNA-seq data analysis
Paired-reads that passed standard quality control13,15 were simultaneously aligned to the 
human genome (GRCh37/hg19) using HISAT (Hierarchical Indexing for Spliced Alignment 
of Transcripts)22, and aligned to human transcriptome (RefSeq) via Bowtie23. One base-pair 
mismatch was set in each alignment. Paired-end aligned reads were used for further analysis. 
Alignment files were transformed into Pileup files for determination of coverage with 
Samtools (mpileup). Expression of each gene in each sample was determined based on 
alignment files from the human transcriptome (RefSeq).
Gene expression of each sample was compared to data reported for 13 EBV-B controls 
present in the Genotype-Tissue Expression (GTEx) project24.
Validation of cryptic deletions
Quantitative PCR (qPCR) was performed for validation of the two cryptic deletions. 
Genomic reference sequences (GRCh37/hg19) of each deleted region were used for primer 
design with Primer3 Web and NCBI Primer-Blast (Supplementary Table 2). Melting curve 
analysis was carried out for each pair of primers to ensure specificity of the PCR 
amplification, and the standard curve method was used to determine PCR efficiency (within 
a range from 95% to 105%).
Each reaction was performed in quadruplicate in 10 μl of reaction mixture simultaneously in 
cases and control (DNA from YH EBV-B cell line13) on a StepOnePlus Real-Time PCR 
System (Applied Biosystems) with SYBR Premix Ex Taq Tli RNaseH Plus (Takara 
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Biotechnology Co., Ltd., Dalian, Liaoning, China) with the default setting of the reaction 
condition. The number of copies in each sample was determined by using the ΔΔCt method 
that compared the Ct (cycle threshold) in case to control25. Two independent pairs of 
primers (Supplementary Table 2) were used in quintuplicate for validation of each deletion.
Accession Number
The accession number for the RNA-seq data reported in this paper is GSE94043 (NCBI 
Gene Expression Omnibus).
Code availability
All the programs relevant to this pipeline are available at https://sourceforge.net/projects/
bca-analysis/files/BCA.tar.gz/download.
Results
We assessed 1,166 samples with at least 8.25-fold physical coverage (Supplementary Table 
1) using our reported approach with the same parameters13. Four samples (HG02260, 
HG03729, NA18612 and NA20764) were identified to harbor balanced translocations 
(Figures 1A), and four samples (NA20759, HG04152, NA18959 and NA21133) were with 
inversions, the size of which ranged from 57.8 kb to 13.3 Mb (Figures 1A). Among the four 
cases with balanced translocations, two are female and two are male and they originate from 
different ethnic populations (Table 1)11. For the four cases with inversions, all are males and 
also originate from different ethnic populations (Table 2).
G-banded karyotypes were observed to be directly consistent with the WGS data for samples 
HG02260, HG03729, NA20764 and NA20759 (Figure 1B–E), and those of NA18612 were 
consistent but much less obvious (Figure 2A, described below). Sanger results confirmed 
each rearrangement in all eight samples with BCAs (Tables 1, 2, next-generation cytogenetic 
nomenclature26 shown in Supplemental Table 3). Microhomology sequences were identified 
in eight of 16 breakpoints suggesting the rearrangements were mediated by microhomology-
mediated end joining (MMEJ)27 (Tables 1, 2). The remaining eight breakpoints represented 
non-homologous end joining (NHEJ)28 (Tables 1, 2).
Subtle balanced translocation identified by WGS
Breakpoints of the t(16;17)(q23.1;q24.2) (NA18612, Figure 2B) were located in bands 
16q23.1 and 17q24.2, representing translocated segments of 15.0 Mb and 16.2 Mb, 
respectively. Due to similarity in the G-banding pattern and size of the exchanged segments, 
chromosome analysis did not readily identify the translocation (Figure 2A). Therefore, 
metaphase FISH17 was performed using BAC probes (SpectrumOrange: RP11-7D23 at 
16q24.3, SpectrumGreen: RP11-526M7 at 17q25.1 and SpectrumRed: RP11-135N5 at 
17p13.3) in more than 100 cells confirming the t(16;17) (Figure 2C).
Gene disruptions by the breakpoints of balanced translocations
Among the four cell lines with balanced translocations, the eight breakpoints disrupted six 
genes (Table 1, Figures 2D, 2E, 3A, and 3B), four of which resulted in disruption of all 
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transcripts in the derivative chromosomes of the breakpoints. In contrast, none of the 
breakpoints from the four cases with inversions disrupted any gene (Table 2).
The breakpoint in seq[GRCh37/hg19] 16q23.1(75,336,134_75,336,138) (NA18612, Figure 
2D) disrupts the gene encoding craniofacial development protein 1 (CFDP1, NM_006324), 
resulting in aberrant splicing of intron 6 and absence of expression of exon 7. This 
disruption is supported by observation of RNA-seq reads mapping in the non-exonic region 
(Figure 2D) and decreased expression of exon 7 (Figure 2E). Although CFDP1 has been 
reported to be necessary for cell survival and differentiation during tooth morphogenesis in 
organ culture29, it is unlikely to be haploinsufficient [Haploinsufficiency score 
(HI)=14.9%]30.
In contrast, the seq[GRCh37/hg19] 14q31.1(79,839,173_79,839,174) breakpoint of 
46,XX,t(9;14)(q34.2;q31.1) (HG02260) (Figure 3A) disrupts all transcripts of neurexin 3 
(NRXN3), which is likely to be haploinsufficient (HI=0.3%)30. However, expression of 
NRXN3 was not detectable among any of the EBV-B cell lines including cases and controls 
(Figure 3C)24.
Cryptic deletions
The 3q24 breakpoint of 46,XY,t(3;17)(q24;p13.3) (HG03729) was found to include a 5.2 kb 
deletion, seq[GRCh37/hg19] 3q24(143,817,430_143,822,651)x1, while the 17p13.3 
breakpoint has a 4.4 kb deletion, seq[GRCh37/hg19] 17p13.3(2,910,366_2,914,751)x1 
(Table 1, Figure 3D and 3E). Neither deletion was reported previously11 and both were 
confirmed by quantitative PCR (Figure 3D and 3E).
Positional effects
Previous studies show that genes in proximity to the breakpoints of a structural variant (i.e., 
balanced translocation) may be mis-expressed, which is defined as a positional effect5. One 
mechanism for a positional effect is the disruption of topological associated domains (TADs) 
by the SV’s breakpoints6,9,31. Here, we used boundaries predicted from the human IMR90 
fibroblast cell line (GRCh37/hg19)31 for our study, as TADs are highly conserved across 
different cell types and across species32.
Eight TADs were disrupted by the breakpoints from the four translocations. Thirty-four 
genes are located in these eight disrupted TADs, and expression was observed in 16 of these 
genes in normal EBV-B cell lines (Supplemental Table 4). However, mis-expression was not 
observed in any of these 34 genes from our RNA-seq data (Supplemental Table 4), even 
though two of these genes are predicted to be likely haploinsufficient (Supplemental Table 
4). By using the published ChIP-seq data from Encyclopedia of DNA Elements 
(ENCODE)33 in EBV-B cell line GM12878, 22 of the 34 genes have a candidate promoter 
(indicated by H3K4Me3) near to a potential active regulatory element (indicated by 
H3K27Ac)31,33. In addition, from the accessible chromatin landscape34, 19 of the 34 genes 
have highly associated DNA I hypersensitive sites (DHSs) and each of them has at least one 
DHS located in the same partial TAD as the gene and the predicted promoter.
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The breakpoint in seq[GRCh37/hg19] 17q24.2(64,953,078_64,953,079) is likely to be 
located between the CACNG4 promoter (indicated by H3K4Me3) and its potential enhancer 
[indicated by H3K27Ac31,33 and DHSs34, Figure 3F] in a human embryonic stem cell line 
(H1-hESC)33. These data suggest that the translocation would likely result in disruption of 
the interaction between the promoter and enhancer for CACNG432 in this particular cell line. 
However, mis-expression of CACNG4 was not observed in our RNA-seq data from EBV-B 
cell line (Figure 3G). Both the candidate promoter and enhancer for CACNG4 were likely 
located downstream of the breakpoint33 in EBV-B cell line GM12878 (control EBV-B cell 
line, Figure 3F).
Discussion
Balanced chromosomal abnormalities including translocations and inversions, known to 
cause reproductive problems and/or an abnormal phenotype, currently are mainly detected 
by G-banded chromosome analysis. However, subtle or cryptic BCAs are not detectable by 
current methods but may contribute to birth defects in offspring of the carriers due to 
unbalanced segregations35. In the present study, by utilizing existing genomic data from the 
1000 Genomes Project, we demonstrate the feasibility of using WGS in the detection of 
BCAs in samples without prior knowledge of their existence.
In the present study, we set a cutoff of 8.25-fold physical coverage to maximize the inclusion 
of 1,166 samples out of 2,504 based on the evaluation of the false negative rate in our 
previous study (11.1% with 90 million read-pairs with insert sizes ranging from 400 to 600 
bp)13. The exclusion of more than half of all samples (n=1,338) is because of the smaller 
insert size generated (259.1±93.5 bp, Figure 1A); the number of non-chimeric and uniquely 
mapped read-pairs was 97.0±40.2 millions, although the base-coverage reached 7.4-fold on 
average. This indicates that better performance of detecting BCA can be achieved by using 
larger insert sizes to increase physical coverage, thus, increasing the number of supporting 
read-pairs for the potential BCAs.
The prevalence of reciprocal balanced translocations in this dataset is one in 291.5 (0.34%, 
4/1,166), which is higher than the rate reported estimated by G-banded chromosome 
analysis1–3. This estimate may be biased due to the limited sample size (N=1,166). However, 
the reported incidences may be underestimated as cryptic or subtle rearrangements, such as 
that observed for 46,XY,t(16;17)(q23.1;q24.2) (NA18612) may not be readily identified by 
conventional G-banded chromosome analysis (Figure 3). Another explanation might be that 
the detection of rearrangements was based on WGS of EBV-B cell line-derived DNAs, 
which might have EBV-B specific genomic variants owing to the introduction of genomic 
instability by EBV infection or the conditions of cell culture36. However, as the EBV-B 
specific genomic variants frequently exist as mosaics36, giving the 100% consistency of 
more than 100 metaphases in each sample in the present study and the WGS data of these 
samples used for our analysis were generated from early batches of EBV-Bs in the 1000 
Genomes Project, balanced translocations detected probably represent the true events in the 
subjects’ peripheral blood samples. Nonetheless, our approach reports the true events 
existing in the tested EBV-B cell lines.
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In addition to the detection of balanced translocations, the microscopic inversion and three 
submicroscopic inversions identified (Table 2) were each unique to a single subject among 
all 1,166 samples analyzed. One explanation for not identifying common or recurrent 
inversions is that they may be mediated by repetitive elements28, for which sequencing with 
small-insert library might not be able to detect37. Sequencing with mate-pair library (or large 
insert library) might be able to overcome such challenge and can also largely reduce the 
sequencing cost by reducing the read-pair amount required13,19. Nonetheless, the 
identification of both balanced translocations and inversions underscores the importance of 
using low-pass WGS for nucleotide level precision of chromosomal rearrangements in 
cytogenetic diagnoses, and brings the future of implementing sequencing a step closer as the 
first tier test.
Gene disruptions were observed in six out of the eight breakpoints in four cases with 
balanced translocations, and NRXN3, a likely haploinsufficient gene, was disrupted 
(HG02260). Heterozygous deletion of NRXN3 is reported in autism spectrum disorder 
(ASD)38. Although this participant in the 1000 Genomes Project is assumed to be healthy at 
the time of enrollment, a possible explanation for the absence of ASD in this presumably 
normal individual would be lack of penetrance38 in the absence of a positive comprehensive 
medical assessment or some technical failure in the process.
Two cryptic deletions involving both breakpoints were identified in t(3;17)(q24;p13.3) 
(HG03729) and neither of them were reported previously11. Two possible reasons for missed 
detection in the previous study11 are: (1) only a limited number of reads mapping in these 
regions (Figure 3D and 3E) resulting in read-depth differences insufficiently sensitive for 
identification, and (2) absence of intra-chromosomal aligned read-pairs supporting these two 
deletions. Genomic imbalance commonly involves the breakpoint of balanced translocations 
and some of them are known to be pathogenic or likely pathogenic6, thus, indicating the 
importance of identification.
No aberration in gene expression resulted from a positional effect, such as disruption of 
TADs as observed in our EBV-B cell line-derived RNA-seq data from four cases with 
balanced translocations. One explanation is that expression was only observed in 16 out of 
the 34 genes in normal EBV-B (Supplemental Table 4), and an effect of dysregulated lower 
expression cannot be detected for genes without detectable expression in the EBV-B cell 
lines24. In addition, another reason would be the proximate interaction between promoter 
and enhancer: (1) 22 of the 34 genes have a candidate promoter near to a potential active 
regulatory element31,33; and (2) 19 of the 34 genes have highly associated DHSs34, and each 
of them has at least one DHS located in the same partial TAD as the gene and the predicted 
promoter, indicating some residual interactions remains between promoter and regulatory 
elements, thus, the disruption of TADs is likely insufficient to alter the gene expression. As 
data from RNA expression provides evidence for confirming potential effects attributed to a 
chromosomal rearrangement, it indicates the importance of combining RNA expression 
analysis with identification of BCAs based on DNA samples for clinical interpretation.
We observed a potential disruption of an interaction between the promoter and an enhancer 
for the 17q24.2 breakpoint (NA18612) in H1-hESC, which serves as a reference for disease 
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association prediction31. However, mis-expression of CACNG4 was not observed in our 
RNA-seq data from the EBV-B cell line (Figure 3G). One explanation is that both the 
candidate promoter and enhancer for CACNG4 are likely located downstream of the 
breakpoint33 in the EBV-B cell lines (GM12878, Figure 3F). As another sample type from 
this subject is not obtainable for further validation, this argues the common usage of 
peripheral blood as a valuable sample type for disease studies beyond its simple availability.
Overall, this study is the first reported investigation utilizing low-pass WGS to explore 
detection of BCAs among samples from the 1000 Genome Project without prior knowledge 
of a chromosomal abnormality. In addition, disruption of gene, cryptic imbalances and 
potential disruption of promoter and enhancer interaction were observed in the four cases 
with balanced translocations, demonstrating the advantage of detecting the breakpoints in 
BCAs by molecular methods via paired-end sequencing and Sanger sequencing, and has 
important implications for a new dawn of improved diagnostics in clinical cytogenetics.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Spectrum of inter- and intra-chromosomal balanced rearrangements and cytogenetic 
validations
Distributions of the average insert sizes and read-pair amounts of 2,504 samples from the 
1000 Genomes Project are shown in (A) and (B), respectively. Insert size and read-pair 
amounts were calculated based on non-chimeric and uniquely mapped read-pairs. (C) 
Spectrum of BCAs. Balanced translocations are indicated with red lines and the 
corresponding sample IDs are shown in red font in each affected chromosome in the outmost 
circle. Inversions are indicated in blue lines and sample IDs are shown in blue font. 
Chromosomal nucleotide positions and bands are shown according to the UCSC Genome 
Viewer Table Browser. In figures (D), (E) and (F), validation of balanced translocations and 
inversion (G) by G-banded chromosome analysis are shown. Ideograms of the balanced 
rearrangements are shown on the left, while the karyogram images are to the right with the 
corresponding ideogram of the derivative chromosomes for reference. Breakpoint regions 
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are indicated with red arrows. Sample name and the International System for Human 
Cytogenomic Nomenclature (ISCN) description are shown below each.
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Figure 2. A subtle translocation t(16;17)(q23.1;q24.2) (NA18612) and the aberrant splicing of 
intron 6 of CFDP1 (NM_006324)
(A) Validation from chromosome analysis. Ideograms of the derivative balanced 
translocation chromosomes are shown with the corresponding G-banded chromosome pairs. 
Breakpoint regions are indicated with red arrows. (B) PCR validation of the junction of 
DNA sequences from the two derivative chromosomes indicated by red arrows while absent 
in the negative control. (C) Validation from FISH. BAC probes are shown with the targeted 
bands (16q24.3 in SpectrumOrange, 17p13.3 in SpectrumRed and 17q25.1 in 
SpectrumGreen, respectively). Derivative chromosomes and normal chromosomes are 
designated with arrows. (D) In the der(17), the genomic location of anti-sense gene CFDP1 
(NM_006324) is shown with the breakpoint mapping in intron 6 (red dotted line). RNA-seq 
read-pairs align to the region (expressed as coverage) proximal to the breakpoint in 
seq[GRCh37/hg19] 16q23.1(75,336,134_75,336,138). It includes the intergenic region in 
17q24.2 and the partial intron 6 of CFDP1 (NM_006324) in 16q23.1 (two grey dotted lines), 
indicating the aberrant splicing of intron 6. (E) Transcript coverage was plotted with the 
paired-end aligned reads (RNA-seq). The coverage of each coordinate is divided by the 
average coverage in this transcript, and subsequently normalized coverage with the average 
coverage from the other three EBV-B cell lines from the 1000 Genomes Project. Black arrow 
indicates low expression in exon 7 that is the absence of exon 7 in the disrupted transcript.
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Figure 3. Gene disruption, cryptic deletions and potential disruption of interaction between 
promoter and enhancer by the breakpoints of balanced translocations
Figures (A), (B) and (C) NRXN3 disruption in 46,XX,t(9;14)(q34.2;q31.1) (HG02260). (A) 
and (B) Genomic locations of NRXN3 and RXRA are shown with breakpoints indicated by 
red dotted lines. (C)NRXN3 and RXRA expression for the four cases from the 1000 
Genomes Project and for 13 reported EBV-B normal control cell lines (the GTEx project). 
Gene expression for NRXN3 and RXRA in HG02260 are indicated with red arrows. Figures 
(D) and (E) cryptic deletions involved at the breakpoints in translocation 46,XY,t(3;17)
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(q24;p13.3) (HG03729). Two cryptic deletions of seq[GRCh37/hg19] 
3q24(143,817,430_143,822,651)×1 and seq[GRCh37/hg19] 17p13.3(2,910,366_2,914,751)
×1 were detected by read-depth difference algorithm and were further confirmed by 
quantitative PCR. The deleted regions are shown in a yellow background with a red arrow 
while the normal copy-ratio (diploid) is shown in a blue background with a blue arrow. Two 
independent pairs of primers (Supplementary Table 2) were used to perform qPCR in 
quintuplicate for validation of each deletion. The bars in cyan show the relative 
quantification of HG03729, while the bars in blue indicate the negative control. Figures (F) 
and (G) potential disruption of interaction between promoter and enhancer from 
rearrangement in 46,XY,t(16;17)(q23.1;q24.2) (NA18612) in H1-hESC. (F) Genes and the 
ChIP-seq data from the ENCODE Project are shown in terms of the genomic location. Each 
cell line with the ChIP-seq data (i.e., H3K4Me3 and H3K27Ac)33 is labeled with a red 
arrow. Breakpoint in seq[GRCh37/hg19] 17q24.2(64,953,078_64,953,079) is shown by a 
green vertical line, while the candidate promoters and enhancers are indicated with orange 
and blue arrows, respectively. The region of potential enhancer in H1-hESC is highlighted in 
DNase I Hypersensitivity Clusters34 in a blue rectangle (DHS region). The figure below is 
zoomed in on the potential enhancer region in H1-hESC. Enrichment of H3K4Me1 and 
absence of H3K4Me3 support a potential active enhancer in this region33,39, while 
enrichment of DNA-binding sequence motifs also indicates the candidate region of the 
interaction for regulatory elements33. (G) Gene expression level (Read Per Kilobase 
Million) of the four cases and 13 EBV-B normal control samples (GTEx project)24.
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